Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 30, 2024 | $0.20 | 2024-06-14 | 2024-06-15 |
| May 31, 2024 | $0.20 | 2024-05-14 | 2024-05-15 |
| April 30, 2024 | $0.20 | 2024-04-12 | 2024-04-15 |
| March 31, 2024 | $0.20 | 2024-03-14 | 2024-03-15 |
| February 29, 2024 | $0.20 | 2024-02-14 | 2024-02-15 |
Dividends Summary
- Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has issued 58 dividend payments over the past 6 years
- The most recent dividend was paid 479 days ago, on June 30, 2024
- The highest dividend payed out to investors during this period was $0.59 per share
- The average dividend paid during this period was $0.26 per share.
Company News
Fortress Biotech and its subsidiary Cyprium Therapeutics received a Complete Response Letter from the FDA regarding the New Drug Application for CUTX-101, citing manufacturing facility cGMP deficiencies, which negatively impacted the company's stock price.
Fortress Biotech announced the closing of the sale of its subsidiary Checkpoint Therapeutics to Sun Pharmaceutical Industries Limited. The transaction will generate approximately $28 million for Fortress and a 2.5% royalty on net sales of Checkpoint's FDA-approved drug UNLOXCYT.
Fortress Biotech CEO Dr. Lindsay A. Rosenwald has increased his stake in the company by purchasing $36.7k worth of Series A Cumulative Perpetual Preferred Stock. This move demonstrates the CEO's confidence in the company's future prospects.